In vivo and in vitro biotransformation of the lithium salt of gammamlinolenic acid by three human carcinomas
1997

Metabolism of Lithium Gamma-Linolenate in Human Tumors

Sample size: 6 publication Evidence: moderate

Author Information

Author(s): R de Antueno, M Elliot, G Ells, P Quiroga, K Jenkins, D Horrobin

Primary Institution: Scotia Research Institute

Hypothesis

Can lithium gamma-linolenate (LiGLA) be effectively metabolized by human carcinomas?

Conclusion

The study found that LiGLA is well tolerated and leads to increased levels of gamma-linolenic acid (GLA) and dihomo-gamma-linolenic acid (DGLA) in various tissues.

Supporting Evidence

  • LiGLA was administered to mice and showed a maximum uptake of radioactivity in organs 30 minutes after infusion.
  • GLA and DGLA levels remained higher in tumor tissues compared to liver and plasma for up to 96 hours.
  • Different human carcinoma cell lines showed varying abilities to metabolize GLA and produce DGLA and AA.

Takeaway

This study looked at how a special fat called LiGLA is used by cancer cells, showing it can stay in tumors for a long time and might help in cancer treatment.

Methodology

The study involved in vivo experiments with nude mice and in vitro experiments with human carcinoma cell lines to assess the metabolism of LiGLA.

Limitations

The study was conducted in a mouse model, which may not fully replicate human responses.

Participant Demographics

Seven-week-old athymic CD1BR (nu/nu) mice were used in the study.

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication